Data Section

Global Healthcare Data

Global Healthcare Data
Diseases

Cancer	Cancer is one of the leading causes of death in the world with the fastest rate of increase (+44%) from 2000 to 2019.	Olympus continues to provide solutions to improve patient outcomes in many of the disease areas.	Lung, Colorectal, Prostate, Stomach, and Liver cancers will remain the Top 5 by volume addressable cancers over the longterm with significant growth in absolute incidence. Stomach cancer is projected to be the fastest growing and followed bycancers of the Esophagus, Pancreas and Bladder.	The overall opportunity to improve the standard of care and patient outcomes will continue to grow significantly across
Olympus-addressable cancers.

Top Causes of Death, World2000

201905101520(Millions)

Increase in New Cancer Cases, World*, 2020–2040

Cardiovascular diseases
Cancer (Neoplasms)

0

Chronic respiratory diseases

1,000,000

2,000,000

Digestive diseases

LungLower respiratory infections
Disease areas Olympus iscurrently offering products
and services

Dementias
Diabetes
Chronic liver diseases
Chronic kidney disease

Health Expenditure per Capita and CAGR* (selected countries)
02,5005,000

United StatesBladder– 0.2%

Japan

+0.8%

United KingdomOvary

+37%

Brain

+35%

Source: Ferlay J, Laversanne M,Ervik M, Lam F, Colombet M, Mery
L, Piñeros M, Znaor A,
Soerjomataram I, Bray F (2020).
Global Cancer Observatory: Cancer
Tomorrow. Lyon, France:
International Agency for Research
on Cancer. https://gco.iarc.fr/
tomorrow, accessed June 28, 2022.

+23%	Lung, Colorectal, Liver, Stomach, and Esophageal cancers will remain the Top 5 by volume addressable cancer deaths overthe long term. Deaths from Prostate and Bladder cancers are projected to be the fastest growing with 92% and 80% increase
respectively, from 2020 to 2040.

12,500(U.S. dollars)

Increase in New Cancer Deaths, World*, 2020–2040
0500,000

1,000,000

1,500,000

Spain

Colorectal
Liver
Stomach– 0.3%– 0.5%

Russian Federation+1.6%

South Africa– 1.7%+0.2%+12.4%
1.1%

Egypt, Arab Rep.

+3.2%

India

+3.9%

Pancreas

+80%

Brain

+41%

Ovary

+48%

Thyroid+71%+72%

3,500,000

Cancer Deaths (N)+64%+68%+70%
+68%

+92%

Bladder

Gallbladder3,000,000+64%

Prostate*CAGR: 2010–2019Source: World Bank, World HealthOrganization Global HealthExpenditure database
https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?
end =2019&start=2000&type=points&view=chart

2,500,000+61%

Esophagus+7.2%

Brazil2,000,000

Lung– 1.1%

Saudi Arabia

Olympus Integrated Report 2022

+62%

+1.1%

Italy

96

Pancreas*Selected cancers that Olympus iscurrently offering products andservices– 0.0%

FranceChina

10,000+1.9%

Canada

+59%
+40%

2010

+3.7%

Germany

Colombia

2019
7,500+59%+64%

Cervix uteri

Thyroid	The U.S. healthcare expenditure per capita is by far the largest and growing at the compound annual growth rate (CAGR)
of 3.7% from 2010 to 2019. The health spending per capita in China has been growing significantly with more than 12%
CAGR.	Olympus is contributing to improve healthcare access globally through supporting healthcare professionals training etc.

+58%
+66%

LiverEsophagus

Health Expenditure

New Cases (N)+56%

Prostate
StomachSource: Causes of death, Our WorldIn Data (2019); IHME, Global Burdenof Disease
https://ourworldindata.org/grapher/annual-number-of-deaths-by-cause

Diarrheal diseases4,000,000+59%

Colorectal

Neonatal disorders

Mexico3,000,000*Selected cancers that Olympus iscurrently offering products andservices
Source: Ferlay J, Laversanne M,Ervik M, Lam F, Colombet M, Mery
L, Piñeros M, Znaor A,
Soerjomataram I, Bray F (2020).
Global Cancer Observatory: Cancer
Tomorrow. Lyon, France:
International Agency for Research
on Cancer. https://gco.iarc.fr/
tomorrow, accessed June 28, 2022.

97

Data Section

Global Healthcare Data

Colorectal Cancer Incidence
by Selected Countries

GIU.S.

EU5*1Japan

China(Thousands)
1,600

1,200	Colorectal cancer (CRC) is one of the top
commonly diagnosed malignancy types. Itsburden is expected to increase with the risk
factors including family and hereditary history but
most cases are sporadic (increasing with age).	CRC has a long history of natural progression
demonstrated. Olympus, a leader in flexible
endoscopy, is committed to its part in the fightagainst CRC with the mission to raise awarenessand ensure early detection.

Colonoscopy
Total Cumulative
Growth in the U.S.
(2009-2019)*2

Gastric Cancer Patients—
Incidence by Region
U.S.

China+22 %

800600400

400200002020

Urology

EU5*12020

2040

Bladder Cancer Patients—
Incidence by Selected Countries
Japan

China(Thousands)
500

400300	Bladder cancer is one of the common cancers
worldwide. With its high prevalence, in conjunction
with its vulnerability to multiple recurrences andprogression despite local therapy, leads to a
substantial health service burden globally.	Olympus is focused around decreasing bladdercancer recurrence through improved detection
and resection of non-muscle invasive tumors andenhancing health outcomes and patient
experiences.

CystoscopyTotal Cumulative
Growth in the U.S.
(2009-2019)*22040

BPH—Diagnosed Prevalenceby Selected Countries
U.S.

EU5*1Japan

China(Millions)+10 %500400	Benign Prostatic Hyperplasia (BPH) affects 50% of men aged 51–60 years of age(including undiagnosed)*3. Symptoms often start mildly, but typically develop further
over time and require different types of therapies in line with severity. The majority ofBPH patients are Mild (43%) or Moderate (38%) while 19% are Severe.	For years Olympus has been an innovator in developing and marketing procedural
solutions for BPH, with electrodes for resection, vaporization and enucleation. By
providing new therapeutic solutions with the iTind device, Olympus will continue to bea global market leader in Urology.

300200

200

100

100002020

2040

Respiratory

Non-Small Cell Lung Cancer(NSCLC) Patients—
Incidence by Selected Countries
U.S.

Japan(Thousands)

800

U.S.

EU5*1	Gastric cancer remains one of the most common and deadly cancers worldwide,
especially among older males. China is a country with a large population of affectedpatients.	Gastric cancer incidence and mortality are highly variable by region and highlydependent on diet and Helicobacter pylori infection.	Olympus, a leader in flexible endoscopy, manufactures gastroscopes for the diagnosis
and treatments of gastric cancers. When gastric cancer is detected in its early stages,
endoscopic resection is a common approach of treatment with shorter hospital stayand faster return to normal life than conventional open surgery.

EU5*1Japan

China(Thousands)
2,000

1,500

1,000

500

02020

20402020	Lung cancer is by far the leading cause of cancer
death. Non-Small Cell Lung cancer (NSCLC)
represents 85% of lung cancer types, 15% being
Small Cell Lung cancer (SCLC). The burden of
NSCLC is expected to increase to nearly 1.5 times innew cases by 2040 from 2020 (U.S., EU5, Japan,China). The highest incidence with fastest evolution
can be found in China. Main risk factors are cigarettesmoking, secondhand smoke, and exposure toharmful chemicals.	Olympus’ mission is to improve outcomes for patients
with, or at risk of, having lung cancer by elevating thestandard of care across diagnosis and staging.	Olympus contributes to the advancements inthoracic imaging through the increased detection ofsmall solitary pulmonary nodules (SPNs)

Bronchoscopy
Total Cumulative
Growth in the U.S.
(2009-2019)*22040

COPD Patients—
Diagnosed Prevalenceby Selected Countries
U.S.

EU5*1

Japan

China(Millions)+63 %1007550	Chronic Obstructive Pulmonary Disease (COPD) entails a group of lung conditions thatcause breathing difficulties. It is the 3rd leading cause of death worldwide.
Environmental exposure to tobacco smoke, air pollution and occupational dusts, fumesand chemicals are important risk factors for COPD.	COPD is sometimes called emphysema or chronic bronchitis. Diagnosed prevalence ofCOPD patients is forecasted to increase from approx. 75 million in 2020 to more than
90 million in 2040 (U.S., EU5, Japan, China). China is the highest and fastest increasing
diagnosed prevalence of COPD patient population.	Olympus endobronchial valve Spiration Valve System (SVS) is used for emphysema
patients when medicines have no effect or in which neither a lung reduction procedure
nor transplant surgery is not applicable. It is also used to treat postoperative prolonged
air leaks arising from a pneumothorax or lung surgery.

25020202040*1 EU5: UK, France, Italy, Germany, Spain
Source: Epi Database, Cerner Enviza. Accessed June 2022.
*2 Source: Compiled from Merative MarketScan Outpatient View database released in 2011 and 2021. MarketScan is a registered trademark of Merative in the United States, other countries or both.
*3 Source: BPH: surgical management – Urology Care Foundation website: www.urologyhealth.org. Updated July 201398

Olympus Integrated Report 202299